The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28131713 |
75 |
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. |
Merck Research Laboratories |
| 26965854 |
96 |
Isoindolinone compounds active as Kv1.5 blockers identified using a multicomponent reaction approach. |
Astrazeneca |
| 25801931 |
24 |
Pseudosaccharin amines as potent and selective KV1.5 blockers. |
Bristol-Myers Squibb Research and Development |
| 24881566 |
140 |
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). |
Glaxosmithkline |
| 25155913 |
32 |
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. |
Astrazeneca |
| 24881565 |
15 |
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors. |
Bristol-Myers Squibb Research and Development |
| 24824064 |
48 |
Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). |
China Pharmaceutical University |
| 23414837 |
35 |
Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists. |
Bristol-Myers Squibb |
| 23121096 |
86 |
Ion channels as therapeutic targets: a drug discovery perspective. |
Pfizer |
| 23260347 |
58 |
Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5. |
Astrazeneca |
| 22770500 |
219 |
3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. |
Astrazeneca |
| 24900546 |
29 |
Symmetric kv1.5 blockers discovered by focused screening. |
TBA |
| 22409629 |
15 |
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor. |
Bristol-Myers Squibb |
| 18374568 |
14 |
Pyrano-[2,3b]-pyridines as potassium channel antagonists. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17506538 |
27 |
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation. |
Cardiome Pharma |
| 11356099 |
20 |
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. |
Abbott Laboratories |
| 21634377 |
73 |
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. |
Amgen |
| 20974533 |
99 |
Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. |
Glaxosmithkline |
| 20304642 |
41 |
Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. |
Merck Research Laboratories |
| 20097068 |
26 |
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers. |
Bristol-Myers Squibb Pharmaceutical Research and Development |
| 19665893 |
29 |
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists. |
Bristol-Myers Squibb |
| 19888755 |
43 |
Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. |
Wyeth Research |
| 19398199 |
24 |
Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel. |
Icagen |
| 19004630 |
35 |
Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)). |
Bristol-Myers Squibb |
| 17462888 |
38 |
Benzopyran sulfonamides as KV1.5 potassium channel blockers. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17350840 |
9 |
Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel. |
Icagen |
| 17125248 |
24 |
Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. |
Merck Research Laboratories |
| 17095219 |
20 |
Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. |
Procter and Gamble Pharmaceuticals |
| 17010606 |
6 |
Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. |
Procter & Gamble Pharmaceuticals |
| 16949818 |
41 |
Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. |
Merck Research Laboratories |
| 16942878 |
8 |
Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers. |
Procter and Gamble Pharmaceuticals |
| 16942874 |
10 |
Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers. |
Procter & Gamble Pharmaceuticals |
| 16793267 |
2 |
Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation. |
Procter & Gamble Pharmaceuticals |
| 16480279 |
71 |
A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. |
Institute of Medical Research Biotechnology Centre |
| 15125940 |
30 |
Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. |
Aventis Pharma Deutschland |
| 12570371 |
33 |
Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. |
Aventis Pharma Deutschland |
| 32248693 |
73 |
Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. |
University of Washington |
| 27660686 |
28 |
Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor. |
Bristol-Myers Squibb |
| 30869888 |
61 |
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. |
TBA |
| 30879840 |
36 |
Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents. |
Astrazeneca |
| 9804693 |
20 |
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity. |
University of Kiel |
| 30538065 |
48 |
The discovery and optimization of benzimidazoles as selective Na |
Pfizer |
| 24513046 |
28 |
Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel. |
Astrazeneca |
| 24071446 |
39 |
Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. |
China Pharmaceutical University |
| 28802123 |
89 |
Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
University of Ljubljana |
| 28753313 |
45 |
Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid) |
Sage Therapeutics |
| 28530802 |
121 |
Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation. |
Vanderbilt University Institute of Imaging Science |
| 28418664 |
32 |
Selective I |
Bristol-Myers Squibb |
Search and Browse
